Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 291

1.

Characterization of prescription opioid abuse in the United States: focus on route of administration.

Kirsh K, Peppin J, Coleman J.

J Pain Palliat Care Pharmacother. 2012 Dec;26(4):348-61. Review.

PMID:
23675595
2.

Use of prescription opioids with abuse-deterrent technology to address opioid abuse.

Michna E, Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R.

Curr Med Res Opin. 2014 Aug;30(8):1589-98. doi: 10.1185/03007995.2014.915803. Epub 2014 Apr 24.

PMID:
24738694
3.

Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.

Stanos S.

Phys Sportsmed. 2012 Nov;40(4):12-20. doi: 10.3810/psm.2012.11.1975. Review.

PMID:
23306411
4.

Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States.

Cicero TJ, Surratt H, Inciardi JA, Munoz A.

Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):827-40.

PMID:
17636553
5.

Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies.

Slevin KA, Ashburn MA.

J Opioid Manag. 2011 Mar-Apr;7(2):109-15.

PMID:
21561034
6.

Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice.

Gudin J.

J Pain Palliat Care Pharmacother. 2012 Jun;26(2):136-43. doi: 10.3109/15360288.2012.679724.

PMID:
22764852
7.

American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I--evidence assessment.

Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR, Bruel BM, Bryce DA, Burks PA, Burton AW, Calodney AK, Caraway DL, Cash KA, Christo PJ, Damron KS, Datta S, Deer TR, Diwan S, Eriator I, Falco FJ, Fellows B, Geffert S, Gharibo CG, Glaser SE, Grider JS, Hameed H, Hameed M, Hansen H, Harned ME, Hayek SM, Helm S 2nd, Hirsch JA, Janata JW, Kaye AD, Kaye AM, Kloth DS, Koyyalagunta D, Lee M, Malla Y, Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel VB, Sehgal N, Silverman SM, Singh V, Smith HS, Snook LT, Solanki DR, Tracy DH, Vallejo R, Wargo BW; American Society of Interventional Pain Physicians..

Pain Physician. 2012 Jul;15(3 Suppl):S1-65.

8.

Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.

Cicero TJ, Ellis MS.

JAMA Psychiatry. 2015 May;72(5):424-30. doi: 10.1001/jamapsychiatry.2014.3043.

PMID:
25760692
9.

American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance.

Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR, Bruel BM, Bryce DA, Burks PA, Burton AW, Calodney AK, Caraway DL, Cash KA, Christo PJ, Damron KS, Datta S, Deer TR, Diwan S, Eriator I, Falco FJ, Fellows B, Geffert S, Gharibo CG, Glaser SE, Grider JS, Hameed H, Hameed M, Hansen H, Harned ME, Hayek SM, Helm S 2nd, Hirsch JA, Janata JW, Kaye AD, Kaye AM, Kloth DS, Koyyalagunta D, Lee M, Malla Y, Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel VB, Sehgal N, Silverman SM, Singh V, Smith HS, Snook LT, Solanki DR, Tracy DH, Vallejo R, Wargo BW; American Society of Interventional Pain Physicians..

Pain Physician. 2012 Jul;15(3 Suppl):S67-116.

10.

Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting.

Brown J, Setnik B, Lee K, Wase L, Roland CL, Cleveland JM, Siegel S, Katz N.

J Opioid Manag. 2011 Nov-Dec;7(6):467-83.

PMID:
22320029
11.

Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.

Gasior M, Bond M, Malamut R.

Postgrad Med. 2016 Jan;128(1):85-96. doi: 10.1080/00325481.2016.1120642. Epub 2015 Dec 18. Review.

PMID:
26566680
12.

The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.

Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, Coplan P, Chilcoat HD.

Drug Alcohol Depend. 2014 Jun 1;139:9-17. doi: 10.1016/j.drugalcdep.2014.02.018. Epub 2014 Feb 26.

PMID:
24721614
13.

Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.

Larochelle MR, Zhang F, Ross-Degnan D, Wharam JF.

JAMA Intern Med. 2015 Jun;175(6):978-87. doi: 10.1001/jamainternmed.2015.0914.

PMID:
25895077
14.

Candidate metrics for evaluating the impact of prescriber education on the safe use of extended-release/long-acting (ER/LA) opioid analgesics.

Willy ME, Graham DJ, Racoosin JA, Gill R, Kropp GF, Young J, Yang J, Choi J, MaCurdy TE, Worrall C, Kelman JA.

Pain Med. 2014 Sep;15(9):1558-68. doi: 10.1111/pme.12459. Epub 2014 May 15.

PMID:
24828968
15.

Opioids for low back pain.

Deyo RA, Von Korff M, Duhrkoop D.

BMJ. 2015 Jan 5;350:g6380. doi: 10.1136/bmj.g6380. Review.

16.
17.

Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation.

Butler SF, Black R, Grimes Serrano JM, Folensbee L, Chang A, Katz N.

Pain Med. 2010 Jan;11(1):81-91. doi: 10.1111/j.1526-4637.2009.00737.x. Epub 2009 Nov 25.

PMID:
20002324
18.

Clinical strategies for the primary health care professional to minimize prescription opioid abuse.

Gudin JA.

Postgrad Med. 2012 May;124(3):131-8. doi: 10.3810/pgm.2012.05.2556. Review.

PMID:
22691907
19.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
20.

The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.

Coplan PM, Chilcoat HD, Butler SF, Sellers EM, Kadakia A, Harikrishnan V, Haddox JD, Dart RC.

Clin Pharmacol Ther. 2016 Sep;100(3):275-86. doi: 10.1002/cpt.390. Epub 2016 Jun 22. Erratum in: Clin Pharmacol Ther. 2017 Apr;101(4):541.

Supplemental Content

Support Center